)
Ovid Therapeutics (OVID) investor relations material
Ovid Therapeutics Status update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic vision and opportunity
Advancing a novel class of CNS medicines targeting KCC2, a master regulator of neural excitation/inhibition balance, with a focus on broad syndromic psychosis and neural hyperexcitability conditions.
Lead oral molecule OV4071 is positioned for development in schizophrenia, Parkinson’s disease psychosis, Lewy body dementia, and other large indications.
Multiple proof-of-concept and clinical studies are planned, including phase II in schizophrenia and exploratory studies in neurodegenerative psychoses, with milestones anticipated through 2026–2027.
Commercial opportunity is estimated at over $6 billion for initial indications, with peak revenue projected at $6.8B in 2038.
The company aims to introduce at least one new development candidate annually from its discovery engine.
Pipeline and clinical development
OV4071 is advancing through Phase 1, with proof-of-mechanism ketamine studies and Phase 1b/2 PoC studies planned for 2026–2027.
OV329 targets drug-resistant focal onset seizures, tuberous sclerosis complex, and infantile spasms, with Phase 2 trials and topline results expected by mid-2027.
Additional undisclosed KCC2 activators are in preclinical development.
OV4071 is being developed as a monotherapy, but combination therapy remains a future option.
Strong IP protection extends to 2046, with a pipeline of next-generation KCC2 activators in development.
Scientific rationale and preclinical evidence
KCC2 is uniquely expressed in the CNS, regulates chloride extrusion, restores GABAergic inhibition, and neural network stability.
Direct KCC2 activation cannot be over-modulated, offering a favorable safety profile compared to neurotransmitter-based drugs.
Preclinical models show OV4071 restores E/I balance, improves cognition, and outperforms existing antipsychotics in working memory and task switching.
OV4071 demonstrates rapid, dose-dependent antipsychotic effects, restoring social interaction and cognitive function in preclinical models.
Efficacy demonstrated across >25 pharmacodynamic models, including genetic and stimulant-induced psychosis, with consistent results.
- Pipeline progress, strong safety, and financing extend cash runway into 2029.OVID
Q4 202518 Mar 2026 - OV329 and OV4071 advance in clinical trials, targeting epilepsy and CNS disorders.OVID
Leerink Global Healthcare Conference 202611 Mar 2026 - OV329 and OV4071 advance in CNS disorders, with major clinical data expected within 18 months.OVID
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - OV329 showed strong safety and potent inhibition, supporting Phase 2a trials in epilepsy.OVID
Study Result23 Jan 2026 - $62.7M cash, $14M Q3 loss, $29M royalty gain, cash runway into H2 2026.OVID
Q3 202423 Jan 2026 - Q2 2024 net income reached $8.5M after a 43% workforce cut and $29M royalty liability gain.OVID
Q2 202423 Jan 2026 - Clinical pipeline advances, cash supports operations into 2026, net loss narrows in 2024.OVID
Q4 202423 Jan 2026 - KCC2 direct activators advance to Phase 1 in 2025, targeting broad CNS indications.OVID
KCC2 Download Day 202414 Jan 2026 - Net loss, pipeline progress, and $7M royalty deal highlight urgent funding needs.OVID
Q2 20256 Jan 2026
Next Ovid Therapeutics earnings date
Next Ovid Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage